Beyondspring Inc (BYSI)

$2.25

-0.09

(-3.85%)

Market is closed - opens 7 PM, 16 Jul 2024

Performance

  • $2.21
    $2.29
    $2.25
    downward going graph

    1.78%

    Downside

    Day's Volatility :3.5%

    Upside

    1.75%

    downward going graph
  • $0.65
    $4.00
    $2.25
    downward going graph

    70.96%

    Downside

    52 Weeks Volatility :83.67%

    Upside

    43.75%

    downward going graph

Returns

PeriodBeyondspring IncSector (Health Care)Index (Russel 2000)
3 Months
32.95%
7.0%
0.0%
6 Months
166.91%
5.5%
0.0%
1 Year
112.73%
12.6%
0.0%
3 Years
-77.13%
15.6%
-19.2%

Highlights

Market Capitalization
94.3M
Book Value
- $0.69
Earnings Per Share (EPS)
-0.54
PEG Ratio
0.0
Wall Street Target Price
1.25
Profit Margin
0.0%
Operating Margin TTM
-1099.32%
Return On Assets TTM
-40.68%
Return On Equity TTM
-310.48%
Revenue TTM
1.8M
Revenue Per Share TTM
0.05
Quarterly Revenue Growth YOY
29.799999999999997%
Gross Profit TTM
1.4M
EBITDA
-22.8M
Diluted Eps TTM
-0.54
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Beyondspring Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Downside of 44.44%

Current $2.25
Target $1.25

Technicals Summary

Sell

Neutral

Buy

Beyondspring Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Beyondspring Inc
Beyondspring Inc
-16.43%
166.91%
112.73%
-77.13%
-87.91%
Moderna, Inc.
Moderna, Inc.
-11.92%
18.89%
-0.93%
-53.23%
748.18%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.23%
17.36%
52.44%
86.66%
268.9%
Novo Nordisk A/s
Novo Nordisk A/s
1.22%
33.6%
76.55%
224.35%
496.35%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.18%
11.71%
36.53%
144.26%
177.11%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Beyondspring Inc
Beyondspring Inc
NA
NA
0.0
0.0
-3.1
-0.41
NA
-0.69
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.64
31.64
1.46
44.29
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.22
49.22
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.94
31.94
0.53
17.02
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Beyondspring Inc
Beyondspring Inc
Buy
$94.3M
-87.91%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$47.1B
748.18%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$118.0B
268.9%
31.64
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$635.7B
496.35%
49.22
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.9B
177.11%
31.94
39.46%

Insights on Beyondspring Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 437.5K → 438.0K (in $), with an average increase of 0.1% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -6.36M → -4.15M (in $), with an average increase of 53.1% per quarter

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 224.3% return, outperforming this stock by 301.4%

Institutional Holdings

  • Decheng Capital LLC

    12.70%
  • FMR Inc

    1.15%
  • BlackRock Inc

    0.55%
  • Capstone Capital Wealth Advisors

    0.13%
  • State Street Corporation

    0.08%
  • Y-Intercept (Hong Kong) Ltd

    0.08%

Company Information

beyondspring pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies. we are currently advancing the development of our lead asset plinabulin, a novel cancer therapeutic, in a global phase 3 trial in non-small-cell lung cancer (nsclc) and initiating a pivotal global phase 3 trial in prevention of docetaxel-induced neutropenia. as a tubulin depolymerizing agent, plinabulin works via multiple mechanisms of action to target and alter the tumor microenvironment: 1. immune enhancing effects via dendritic cell maturation 2. tumor cell apoptosis via activation of ras-jnk pathway 3. vascular disruptive effects given plinabulin’s potential as a tumor micro-environment targeting agent, we intend to initiate clinical trials in additional cancer indications: • immuno-oncology, with immune checkpoint inhibitors in nsclc • cns malignancies including glioblastoma (gbm) • kras positive mutant cancers

Organization
Beyondspring Inc
Employees
36
CEO
Dr. Lan Huang Ph.D.
Industry
Health Technology

FAQs